arrow
R

Richard E. Higgs

Eli Lilly and Company
H指数:36
被引数:6,436

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules

亲和捕获-洗脱结合细胞基环腺苷酸测定法,作为一种检测抑制素分子中和抗体的平台方法

2025-10-130
PRE
Comparative molecular analysis of IL-17A and IL-23 pathway inhibition in moderate-to-severe psoriasis: 4-week results from IXORA-R

中重度银屑病中IL-17A与IL-23通路抑制的分子比较分析:IXORA-R研究4周结果

2025-08-150
PREAI
The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms

治疗性单克隆抗体Bamlanivimab不会通过FcR介导的机制增强SARS-CoV-2感染

2023-11-302
OAAI
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
2022-05-01281
OAAI
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
2021-12-0915
OAAI
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
2021-10-2853
OAAI
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
2021-05-12322
OAAI
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial
2021-02-16713
OA
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
2020-10-0946
OAAI
Mechanism of baricitinib supports artificial intelligence-predicted testing inCOVID-19 patients

baricitinib支持人工智能预测测试的机制inCOVID-19患者

2020-06-24207
OAAI